Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis
NCT07580716
This study is recruiting at 4 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Primary Knee Osteoarthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 64 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Enlivex Therapeutics Ltd.
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 2
- Future Medical Research · Longwood, FL
- South Florida Research Phase I-IV · Miami, FL
Louisiana · 1
- DelRicht Research @ Touro Medical Center · New Orleans, LA
Michigan · 1
- Oakland Medical Research · Troy, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.